Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;51(12):1547-1558.
doi: 10.1111/1346-8138.17386. Epub 2024 Oct 14.

Exploring racial and ethnic disparities in the hidradenitis suppurativa patient disease journey: Results from a real-world study in Europe and the USA

Affiliations

Exploring racial and ethnic disparities in the hidradenitis suppurativa patient disease journey: Results from a real-world study in Europe and the USA

Tarannum Jaleel et al. J Dermatol. 2024 Dec.

Abstract

Hidradenitis suppurativa (HS) is an inflammatory skin disease associated with high morbidity and disability that has limited treatment options. People from racial and ethnic minority groups may experience greater disease severity and delay to diagnosis. This study assessed the impact of race/ethnicity on HS diagnosis and management in real-world clinical settings. Data were derived from the Adelphi Real World Hidradenitis Suppurativa Disease Specific Programme, a survey of dermatologists and their consulting HS patients in five European countries and the USA in 2020/2021. Dermatologists returned demographic and clinical data, and treatment goals and satisfaction for their next five to seven consulting patients. Patients completed a questionnaire on disease history and diagnosis, disease burden, and treatment satisfaction. Groups were compared with bivariate tests. In total, 312 physicians returned data on 1787 patients; 57.6% were female and 77.7% White. People from racial and ethnic minority groups were younger than White patients (32.9 ± 11.6 vs. 34.9 ± 12.4, mean ± standard deviation) and reported symptoms at a younger age (23.3 ± 10.8 vs. 26.2 ± 11.1), but their time to first consultation was longer than for White patients (2.6 ± 5.7 vs. 1.2 ± 2.5 years). People from racial and ethnic minority groups took longer to receive a correct diagnosis following first consultation (2.7 ± 5.3 vs. 1.5 ± 4.1 years) and were more likely to be misdiagnosed with boils (73.5% vs. 40.4%). People from racial and ethnic minority groups had a greater disease awareness at diagnosis and reported wanting greater support. People from racial and ethnic minority groups reported a greater impact on life, more severe pain, and a greater level of activity impairment in the Work Productivity and Activity Impairment: General Health (27.0 ± 25.2 vs. 20.0 ± 20.6). All P values were ≤0.05. These data show evidence of delayed diagnosis and higher HS symptom burden amongst people from racial and ethnic minority groups, highlighting health disparities in HS.

Keywords: cross‐sectional study; delayed diagnosis; ethnicity; health equity; hidradenitis suppurativa.

PubMed Disclaimer

Conflict of interest statement

Tarannum Jaleel is an investigator for UCB and Eli Lilly, consults for Eli Lilly and Chemocentryx and receives honoraria, has received funds from Pfizer and UCB for research fellow support, and has received funds from Dermatology Foundation, Skin of Color Society, and NIH K12 (grant number: K12HD043446). Beth Mitchel, Russel Burge, and Dipak Patel are employees of Eli Lilly and Company and minor shareholders of Eli Lilly stock. Andrea Cohee is an employee of Eli Lilly and Company. Hayley Wallinger, Isabel Truman, and Aaron Keal are employees of Adelphi Real World, Bollington, UK.

Figures

FIGURE 1
FIGURE 1
Proportions of patients who agreed with statements about their disease. Agreement was scored on a scale of 1 to 10, where 1 = completely disagree and 10 = completely agree. Data are the mean of agreement scores with bars indicating standard deviation. Categorical values were compared using Mann–Whitney U‐tests. HS, hidradenitis suppurativa; PREG, people from racial and ethnic minority groups.

References

    1. Sabat R, Jemec GBE, Matusiak Ł, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6:18. - PubMed
    1. Dufour DN, Emtestam L, Jemec GB. Hidradenitis suppurativa: a common and burdensome, yet under‐recognised, inflammatory skin disease. Postgrad Med J. 2014;90:216–221; quiz 20. - PMC - PubMed
    1. Kirby JS, Miller JJ, Adams DR, Leslie D. Health care utilization patterns and costs for patients with hidradenitis suppurativa. JAMA Dermatol. 2014;150:937–944. - PubMed
    1. Jemec GB, Kimball AB. Hidradenitis suppurativa: epidemiology and scope of the problem. J Am Acad Dermatol. 2015;73(5 Suppl 1):S4–S7. - PubMed
    1. Phan K, Charlton O, Smith SD. Global prevalence of hidradenitis suppurativa and geographical variation—systematic review and meta‐analysis. Biomed Dermatol. 2020;4:2.

MeSH terms